ClinicalTrials.gg
Sign In
Active, not recruitingNCT07246590COVE-2Updated Oct 23, 2026

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

A Phase 3 interventional study of VP-102 and Vehicle in Common Warts, Common Warts (Verruca Vulgaris) and Human Papilloma Virus (HPV), sponsored by Verrica Pharmaceuticals Inc.. Active, not recruiting at 17 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Verrica Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Updated Oct 23, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Study summary

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Read the detailed description

Methodology:

This Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium 2]) includes a Screening Period of up to 60 days, followed by a 75-day Treatment Period, and a 63-day Follow-up Period.

Treatments:

Treatment Visit 1 (Day 1), the day of the first application of study drug (YCANTH [VP-102] or Vehicle), may occur on the same day as the Screening Visit. Dermatologic examination, wart measurements, location of all treatable common warts, and evaluation of response to treatment (ERT; as defined in Assessments and procedures) must be repeated if the Screening Visit and Treatment Visit 1 do not coincide. YCANTH (VP-102) or Vehicle will be applied by the Investigator or qualified member of the research team. Study drug will be applied to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. Warts are to be treated, then covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and be removed just before the 24 hour evaluation of response to treatment (ERT).

Before application of study drug, wart paring, if necessary, will be completed. If adherent scale is not present, study drug can be applied without paring.

Treatment will continue every 21 (±4) days until complete clearance of all warts or a maximum of 4 treatment sessions during the 75-day treatment period. The exact treatment interval will be determined by evaluation of the treatment site, taking into account ongoing local skin reactions (LSRs), which are defined as temporary local skin reactions (vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema and erosion. that are expected and consistent with historical treatment with YCANTH (VP-102). Subjects will be required to return for every treatment and follow-up visit even if their treatable common warts have cleared. Subjects will have an in- person visit 24 (± 6) hours after Treatment Visit 1 (first application of study drug). After Treatment Visits 2, 3, and 4 (Days 21, 42, and 63, respectively), telephone follow-up will be conducted 24 to 72 hours after application of study drug. In addition, telephone follow-up will be conducted 7 to10 days after application of study drug after Treatment Visits 1,2,3 and 4. During the telephone calls, a member of the research team will complete ERT assessments and inquire about AEs and concomitant medications.

Assessment for complete clearance (i.e., complete resolution of all common warts as assessed visually by a Blinded Assessor) may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated; the visit will be documented as an Unscheduled Visit. The timing of the next visit will be determined by resolution of the LSRs. All LSRs must resolve sufficiently to allow for evaluation of the treatment site. The research team will be in contact with the subject until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. A treatment interval exceeding 21 (± 4) days because of resolving LSRs will not be considered a protocol deviation.

All treatable common warts that are not completely clear should undergo treatment with study drug. No partial treatment of treatable common warts is permitted, unless a subject would be required to exceed the maximum number of 2 applicators per treatment session in order to complete treatment. Each applicator can cover approximately 1500 mm² for a total of approximately 3000 mm² using the 2 study drug applicators.

If a subject receives fewer than 4 treatments within the 75-day treatment period because of the duration of post-treatment LSRs, this will not be considered a protocol deviation. No treatment should be administered after the 75-day treatment period without Sponsor approval.

Subjects will be required to attend all visits even if they have achieved complete clearance of all treatable common warts at a previous visit.

Subjects enrolled in this study (COVE-2) may be eligible to enroll in a Long-Term Follow-up (LTFU) study (Study VP-CW-303 [COVE-4]) to evaluate the safety and efficacy of YCANTH (VP-102) over 54 weeks:

  • Subjects who have completed the in-person Day 84 (0 to + 8 days; End-of-Treatment/End-of-Study 1) Visit and have complete clearance will be assessed at follow-up visits on Day 105 (± 7 days; Follow-up 1/End-of-Study 2) and Day 147 (± 7 days; Follow-up 2/End-of-Study 3).
  • Subjects who have not achieved complete clearance of all treatable common warts by Day 84, and those who have new treatable common warts or recurrence of previously treated warts after Day 84 (ie, at Day 105 or Day 147) may be eligible to transition into the LTFU study.
  • At Day 147, all subjects remaining in COVE-2 may be eligible to transition into the LTFU study for continued follow-up and treatment.

In the LTFU study, subjects will receive open-label YCANTH (VP-102) every 21 days until all treatable common warts are clear (for a maximum of 4 additional treatments) or until Day 357, whichever occurs first.

02

Conditions studied

  • Common Warts
  • Common Warts (Verruca Vulgaris)
  • Human Papilloma Virus (HPV)
  • Warts

Browse trials for

Keywords

  • Common Warts
  • Common Warts (Verruca Vulgaris)
  • Human Papilloma Virus (HPV)
03

In context

Warts

171 studies on the registry are indexed under Warts; 35 are open to participants now.

This study's enrollment of 302 is above the median of 70 across 155 interventional studies indexed under Warts.

Browse Warts studies →

Lead sponsor

Verrica Pharmaceuticals Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Candidates will be included in the study if they:

  1. Are male or female patients ≥ 2 years of age.
  2. Are immunocompetent.

  3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height:

    1. Common warts are considered treatable if they are located anywhere on the body, except for the following excluded areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, soles of the feet (plantar warts), subungual spaces (ie, under the fingernail or toenail), or the anogenital area (warts within 10 mm of a mucosal surface should not be treated).

    2. Common warts located in excluded areas (warts within 10 mm of a mucosal surface) will not be treated or evaluated in this study. Warts that are genital, plantar, or anal are not considered common warts and are thus excluded from treatment and evaluation in this study. A subject will not be excluded from the study if they have these types of warts, but the subject must also have warts that meet the inclusion criteria.

      • If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that are under study.
  4. Have no systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.
  5. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.
  6. Have the ability, or have a parent/guardian with the ability, to follow study instructions and the willingness to complete all study requirements.
  7. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study, with the exception of circumstances allowed under Inclusion Criterion 3b.
  8. Provide written or assent in a manner approved by the IRB and/or have a parent/guardian provide written informed consent as evidenced by the signature on an IRB approved assent/consent form. Subjects who turn 18 years of age (or legal age per state or country) during the study will be required to re-consent to remain on the study.
  9. Provide written authorization for use and disclosure of protected health information (per state and/or country requirements).
  10. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.

Exclusion criteria

Exclusion Criteria:

Candidates will be excluded from the study if they:

  1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.
  2. Have any warts present at Baseline in an allowed anatomic location that the subject, parent/guardian, or Investigator is unwilling to treat.
  3. Plantar warts and external genital warts will not be included in this study, in addition, subungual warts and warts within 10 mm of a mucosal surface will not be included in this study due to their anatomical location and complex treatment modalities.
  4. Are systemically or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral ) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.
  5. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, , systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).
  6. Have had any previous treatment (including an agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 30 days before treatment. NOTE: If there are ongoing local skin reactions 30 days prior to treatment, do not screen for eligibility until they are resolved.
  7. Have more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm² for a total of approximately 3000 mm² using the 2 study drug applicators.
  8. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug and will be recorded as concomitant therapies in the eCRF.
  9. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.
  10. Have epidermodysplasia verruciformis.
  11. Have an active or are undergoing treatment for any malignancy other than basal cell carcinoma.
  12. Have a history or presence of medical, psychiatric, or emotional condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.
  13. Have a history or presence of or an idiosyncratic reaction to the study drug or related compounds, or drug product (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).
  14. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who required hospitalization in the 2 months before screening for an acute or chronic condition including alcohol or drug abuse), as determined by the Investigator.
  15. Are sexually active or may become sexually active and are unwilling to practice a highly effective method of (eg, combination of condoms and foam; oral contraceptives; intrauterine device with or without hormone release; transdermal, injectable, or intravaginal contraception). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with study drug.
  16. Are pregnant or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    VP-102

    Topical solution, which is a light violet to dark purple, slightly viscous liquid. 0.7% (each mL contains 7 mg of cantharidin)/glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period.

    Combination Product: VP-102

  • Placebo comparator
    Vehicle

    Topical solution, which is a light violet to dark purple, slightly viscous liquid. No active drug/glass ampule within an applicator. Each applicator contains 0.45 mL without active cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period.

    Combination Product: Vehicle

Interventions

  • Combination productVP-102

    A single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area.

  • Combination productVehicle

    Vehicle is contained in a single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. The Vehicle applicator contains the same excipient formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.

    To evaluate the efficacy of YCANTH (VP-102) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).

    Time frame: Day 84(0/+8 days)

Secondary outcomes

  1. Proportion of subjects achieving sustained complete clearance of all treatable common warts (baseline and new) from Treatment Visit 4 (Day 63) through EOT Visit (Day 84).

    To evaluate the efficacy of YCANTH (VP-102) relative to Vehicle by assessing the proportion of subjects achieving sustained complete clearance of all treatable common warts (baseline and new) from Treatment Visit 4 (Day 63) through EOT Visit (Day 84)

    Time frame: From Day 63 (=/- 4 days) to Day 84 (0/+8 days)

  2. Proportion of subjects achieving sustained complete clearance of all treatable common warts (baseline and new) from Treatment Visit 3 (Day 42) through EOT Visit (Day 84).

    To evaluate the efficacy of YCANTH (VP-102) relative to Vehicle by assessing the proportion of subjects achieving sustained complete clearance of all treatable Common warts (baseline and new) from Treatment Visit 3 (Day 42) through EOT Visit (Day 84).

    Time frame: From Day 42 (+/- 4 days) to Day 84 (0/+8 days)

  3. Proportion of subjects achieving sustained complete clearance of all treatable common warts (baseline and new) from Treatment Visit 2 (Day 21) through EOT Visit (Day 84).

    To evaluate the efficacy of YCANTH (VP-102) relative to Vehicle by assessing the proportion of subjects achieving sustained complete clearance of all treatable Common warts (baseline and new) from Treatment Visit 2 (Day 21) through EOT Visit (Day 84).

    Time frame: From Day 21 (+/- 4 days) to Day 84 (0/+8 days)

  4. Incidence and severity of AEs (including LSRs) Change from baseline in vital signs (body temperature, pulse rate). Concomitant medication use.

    To assess the safety of YCANTH (VP-102) relative to Vehicle, by assessing concomitant medication use and AEs (AEs), including expected LSRs.

    Time frame: From enrollment to the end of Study (12 weeks to 21 weeks)

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Sites
15 sites added, 4 sites removed
Show 15 added (15 United States)
  • Enchantress Dermatology and Research · Miami, United States
  • Ada West Research · Meridian, United States
  • Delricht Research at Touro Medical Center · New Orleans, United States
  • Maryland Dermatology Laser Skin & Vein · Hunt Valley, United States
  • Aesthetic and Dermatology Center · Rockville, United States
  • US Dermatology Partners · Rockville, United States
  • Michigan Center for Research Company · Clarkston, United States
  • Skin Specialist, PC dba Schlessinger MD · Omaha, United States
  • JDR Dermatology Research · Las Vegas, United States
  • Bexley Dermatology Research · Bexley, United States
  • Optima Research Boardman · Boardman, United States
  • Apex Skin Clinical Research Center · Mayfield Heights, United States
  • Delricht Research at Grassroots Healthcare · Tulsa, United States
  • Tennessee Clinical Research Center · Nashville, United States
  • Texas Dermatology and Laser Specialists, PLLC · San Antonio, United States
Show 4 removed
  • Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein · Hunt Valley, United States
  • Tennessee Clinical Research Center, Inc. · Nashville, United States
  • The University of Texas Health Science Center at Houston · Houston, United States
  • Texas Dermatology and Laser Specialists · San Antonio, United States
Oct 23, 2026
Primary completion
Jun 2027→Nov 2026
Oct 23, 2026
Study completion
Jun 2027→Jan 2027
Oct 23, 2026
Enrollment
300 (estimated)→302 (actual)
Oct 23, 2026
Eligibility
3 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedHave had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 9030 days before treatment. NOTE: If there are ongoing local skin reactions 30 days prior to treatment, do not screen for eligibility until they are resolved.
  • EditedHave more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2mm² for a total of approximately 3000 mm2mm² using the 2 study drug applicators.
  • EditedHave an active malignancy or are undergoing treatment for any malignancy other than basal cell carcinoma.
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Active, not recruiting
    15 sites added, 4 sites removed
    Show 15 added (15 United States)
    • Enchantress Dermatology and Research · Miami, United States
    • Ada West Research · Meridian, United States
    • Delricht Research at Touro Medical Center · New Orleans, United States
    • Maryland Dermatology Laser Skin & Vein · Hunt Valley, United States
    • Aesthetic and Dermatology Center · Rockville, United States
    • US Dermatology Partners · Rockville, United States
    • Michigan Center for Research Company · Clarkston, United States
    • Skin Specialist, PC dba Schlessinger MD · Omaha, United States
    • JDR Dermatology Research · Las Vegas, United States
    • Bexley Dermatology Research · Bexley, United States
    • Optima Research Boardman · Boardman, United States
    • Apex Skin Clinical Research Center · Mayfield Heights, United States
    • Delricht Research at Grassroots Healthcare · Tulsa, United States
    • Tennessee Clinical Research Center · Nashville, United States
    • Texas Dermatology and Laser Specialists, PLLC · San Antonio, United States
    Show 4 removed
    • Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein · Hunt Valley, United States
    • Tennessee Clinical Research Center, Inc. · Nashville, United States
    • The University of Texas Health Science Center at Houston · Houston, United States
    • Texas Dermatology and Laser Specialists · San Antonio, United States
    Primary completion Jun 2027→Nov 2026
    Study completion Jun 2027→Jan 2027
    Enrollment 300 (estimated)→302 (actual)
    Eligibility 3 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedHave had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 9030 days before treatment. NOTE: If there are ongoing local skin reactions 30 days prior to treatment, do not screen for eligibility until they are resolved.
    • EditedHave more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2mm² for a total of approximately 3000 mm2mm² using the 2 study drug applicators.
    • EditedHave an active malignancy or are undergoing treatment for any malignancy other than basal cell carcinoma.
    + 4 other changes: verification date, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07246590
Lead sponsor
Verrica Pharmaceuticals Inc.
Collaborators
Canfield Scientific Inc., Medidata Solutions, Veeva Systems, Torii Pharmaceutical Co. Ltd., Allucent (US) LLC, Myonex
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Dec 17, 2025
Primary completion
Nov 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VP-102

Other studies in this condition

Warts →

Other studies from this sponsor

Verrica Pharmaceuticals Inc.

Start the discussion